Trials
2 active
9 in total · 2 in the EU
What this is
- How it works
- Cortisol Synthesis Inhibitor FDA class
- How it’s given
- “Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical…”In the company’s words, NCT07247162 on ClinicalTrials.gov
- Tested for
- Cushing Syndrome (2 trials), Hypertension, Hypercortisolemia
- Main trialPhase 4
- “Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.”In the company’s words, NCT07247162 on ClinicalTrials.gov
- Other names
- isturisa · LCI699 · osilodrastat
Other drugs for Cushing Syndrome
- RelacorilantCorcept Therapeutics · Phase 2
- ClofutribenSparrow Pharmaceuticals · Phase 2
Coming up2
- 21 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | May 2028 | Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome | |
| Phase 2Recruiting | 21 Jul 2027 | Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | |
| Phase 3Completed | 21 Feb 2018 | Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease | |
| Phase 3Completed | 19 Jun 2019 | Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease | |
| Phase 2Completed | 2 Jul 2009 | A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension | |
| Phase 2Completed | 12 Aug 2009 | A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension | |
| Phase 2Completed | 13 Oct 2009 | A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension | |
| Phase 2Completed | 22 Oct 2019 | Safety and Efficacy of LCI699 in Cushing's Disease Patients | |
| Phase 2Completed | 16 Nov 2023 | Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026